Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commissioner Nominee's Required Divestitures Illustrate US FDA's Broader Recruitment Challenge

Executive Summary

Stephen Hahn will have over 100 stocks to divest upon becoming FDA commissioner.

You may also be interested in...



Hahn May Not Run Into Questions About Industry Ties Like His Predecessors

Nominee for US FDA commissioner has remained largely focused on academic work and private practice, receiving only a few payments from pharma and device companies.

Stephen Hahn For US FDA Commissioner: Will Academic Experience Suffice For Confirmation?

The MD Anderson Cancer Center administrator's lack of significant government administration experience may inspire questions during the confirmation process.

US FDA May Wait Until Late 2019 Before A Cures Hiring Enhancement Is Available

Senior Biomedical Research Service expansion, used to attract elite scientists to federal service, may not be implemented until late 2019; FDA also may have a candidate for OND director.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS141278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel